Mood Changes On A GLP-1: What's The Medication And What's The Life Change?

This is the hardest question in GLP-1 coverage to write about responsibly, because two things are true at once: individual people report real and sometimes significant mood changes, and large population studies have not established that the medication causes them.

Both facts matter. What follows is how clinicians work through it in practice, and where the hard lines are.

What the evidence currently shows

Regulators including the European Medicines Agency and the US Food and Drug Administration have reviewed reports of suicidal thoughts associated with GLP-1 medication and have not found evidence of a causal relationship. Several large observational studies have found no increased risk, and some have found lower rates.

That is genuinely reassuring at population level, and it does not mean nothing is happening to individuals. Rare effects are hard to detect in aggregate data, and “no established causal link” is not the same as “impossible”. The appropriate response is monitoring rather than either alarm or dismissal.

The things that affect mood regardless of the drug

Several are almost universal on this treatment and each independently affects mood.

Under-eating. Sustained low intake affects mood, concentration and irritability. Very low carbohydrate intake in particular is associated with low mood in some people.

Nutrient gaps. Eating substantially less makes deficiency more likely — iron, B12 and vitamin D all have mood effects and all are testable.

Sleep. Disrupted sleep, common during escalation, is one of the strongest predictors of next-day mood there is.

Losing a coping mechanism. If eating was regulating stress, its removal leaves the stress without an outlet.

And the things that improve mood

Worth stating, because the coverage skews negative. Many people report improved mood on treatment: relief from food noise, better sleep, improved mobility, better glycaemic control, and a sense of agency after years of feeling that nothing worked.

There is also emerging interest in GLP-1 receptors in brain regions involved in reward and addiction, with some people reporting reduced compulsive behaviours beyond food. That research is early and should not be oversold.

How to tell them apart

The same discriminator that works elsewhere works here: does it track your dose? Mood dipping reliably in the two days after an injection and lifting later in the cycle points towards a medication effect. A steady low mood with no weekly pattern points elsewhere.

Ask also whether it is confined to one area of life or pervades everything, and whether it preceded the medication. Our piece on burnout versus depression covers those distinctions.

Practically this requires dated notes. Recording mood alongside dose day — in whatever you already use, including a GLP-1 companion app such as Zenday App if you are logging symptoms there anyway — is what turns “I've felt off for a while” into something a clinician can actually assess. That is the entire value of it here: three cycles of dated entries make the pattern visible or rule it out.

Who needs closer monitoring

A personal or family history of depression, anxiety or bipolar disorder. Any history of an eating disorder. Current antidepressant treatment. Previous suicidal ideation.

None of these excludes you from treatment. They are reasons to tell your prescriber before starting and to agree what monitoring looks like — including who you contact and how quickly if things change.

The hard line

New or worsening thoughts of self-harm or suicide require same-day medical attention. Contact your prescriber, your GP, an urgent mental health line or emergency services.

Do not wait for a scheduled review, and do not talk yourself out of it on the grounds that the studies say the drug is not responsible. Whatever the cause, the symptom needs attending to.